Prognostic significance of Bax protein expression in diffuse aggressive non-Hodgkin's lymphoma

Blood

Volumn 90, Issue 8, 1997, Pages 3173-3178

  Gascoyne, Randy D ^b   Krajewska, Maryla ^a   Krajewski, Stanislaw ^a   Connors, Joseph M ^b   Reed, John C ^a  

^a BURNHAM INSTITUTE   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN BCL 2;

ADOLESCENT; ADULT; AGED; APOPTOSIS; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN INDUCTION;

EID: 0030814361     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v90.8.3173     Document Type: Article

References (41)

1. Reed JC: Bcl-2 and the regulation of programmed cell death. J Cell Biol 124:1, 1994
2. Vaux DL, Strasser A: The molecular biology of apoptosis. Proc Natl Acad Sci USA 93:2239, 1996
3. Yang E, Korsmeyer SJ: Molecular thanatopsis: A discourse on the BCL2 family and cell death. Blood 88:386, 1996
4. Tsujimoto Y, Cossman J, Jaffe E, Croce C: Involvement of the bcl-2 gene in human follicular lymphoma. Science 228:1440, 1985
5. Miyashita T, Reed JC: Bcl-2 gene transfer increases relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res 52:5407, 1992
6. Reed JC: Bcl-2: Prevention of apoptosis as a mechanism of drug resistance. Hematol/Oncol Clin North Am 9:451, 1995
7. Hermine O, Haioun C, Lepage E, d'Agay M-F, Briere J, Lavignac C, Fillet G, Salles G, Marolleau J-P, Diebold J, Reyes F, Gaulard P: Prognostic significance of Bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Blood 87:265, 1996
8. Hill ME, MacLennan KA, Cunningham DC, Hudson BV, Burke M, Clarke P, DiStefano F, Anderson L, Hudson GV, Mason D, Selby P, Linch DC: Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: A British national lymphoma investigation study. Blood 88:1046, 1996
9. Campos L, Roualult J-P, Sabido O, Roubi N, Vasselon C, Archimbaud E, Magaud J-P, Guyotat D: High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 81:3091, 1993
10. Moul JW, Mostofi FK, Bauer JJ: Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer. Surgery 120:159, 1996
11. Bauer JJ, Sesterhenn IA, Mostofi FK, McLeod DG, Srivastava S, Moul JW: Elevated levels of apoptosis regulator proteins P53 and BCL-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer. J Urol 156:1511, 1996
12. Yin XM, Oltvai ZN, Korsmeyer SJ: BH1 and BH2 domains of bcl-2 are required for inhibition of apoptosis and heterodimerization with bax. Nature 369:321, 1994
13. Oltvai Z, Milliman C, Korsmeyer SJ: Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74:609, 1993
14. Zhan Q, Fan S, Bae I, Guillouf C, Liebermann DA, O'Connor PM, Fornace Jr AJ: Induction of bax by genotoxic stress in human cells correlates with normal p53 status and apoptosis. Oncogene 9:3743, 1994
15. Miyashita T, Reed JC: Tumor suppressor p53 is a direct transcriptional activator of human bax gene. Cell 80:293, 1995
16. Bargou RC, Wagener C, Bommert K, Mapara MY, Daniel PT, Arnold W, Dietel M, Guski H, Feller A, Royer HD, Dorken B: Overexpression of the death-promoting gene bax-α which is down-regulated in breast cancer restores sensitivity to different apoptotic stimuli and reduces tumor growth in SCID mice. J Clin Invest 97:2651, 1996
17. Sakakura C, Sweeney EA, Shirahama T, Igarashi Y, Hakomori S, Nakatani H, Tsujimoto H, Imanishi T, Ohgaki M, Ohyama T, Yamazaki J, Hagiwara A, Yamaguchi T, Sawai K, Takahashi T: Overexpression of bax sensitizes human breast cancer mcf-7 cells to radiation-induced apoptosis. Int J Cancer 67:101, 1996
18. Wagener C, Bargou RC, Daniel PT, Bommert K, Mapara MY, Royer HD, Dorken B: Induction of the death-promoting gene bax-alpha sensitizes cultured breast-cancer cells to drug-induced apoptosis. Int J Cancer 67:138, 1996
19. Krajewski S, Blomvqvist C, Franssila K, Krajewska M, Wasenius V-M, Niskanen E, Reed JC: Reduced expression of pro-apoptotic gene Bax is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res 55:4471, 1995
20. Maundrell K: nmt1 of fission yeast. J Biol Chem 265:10857, 1990
21. Cossman J: Diffuse, aggressive non-Hodgkin's lymphomas, in Jaffe ES (ed): Surgical Pathology of the Lymph Nodes and Related Organs (vol 16). San Francisco, CA, WB Saunders Company, 1985, p 203
22. Kodura PRK, Filippa DA, Richardson ME, Jhanwar SC, Chaganti SR, Koziner B, Clarkson BD, Lieberman PH, Chaganti RSK: Cytogenetic and histologic correlations in malignant lymphoma. Blood 69:97, 1987
23. Klimo P, Connors JM: MACOP-B chemotherapy for the treatment of diffuse large cell lymphoma. Ann Int Med 102:596, 1985
24. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA, Miller TP: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328:1002, 1993
25. Shipp MA, Harrington DP, Anderson JR, Armitage JO, Bonadonna G, Brittinger G, Cabanillas F, Canellos GP, Coiffier B, Connors JM, Cowan RA, Crowther D, Dahlberg S, Engelhard M, Fisher RI, Gisselbrecht C, Horning SJ, Lepage E, Lister A, Meerwaldt JH, Montserrat E, Nissen NI, Oken MM, Peterson BA, Tondini C, Velasquez WS, Yeap BY: A predictive model for aggressive NHL: The international non-Hodgkin's lymphoma prognostic factors project. N Engl J Med 329:987, 1993
26. Gascoyne RD, Adomat SA, Krajewski S, Krajewska M, Horsman DE, Tolcher AW, O'Reilly SE, Coldman AJ, Reed JC, Connors JM: Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood 90:244, 1997
27. Krajewski S, Krajewska M, Shabaik A, Miyashita T, Wang H-G, Reed JC: Immunohistochemical determination of in vivo distribution of bax, a dominant inhibitor of bcl-2. Am J Pathol 145:1323, 1994
28. Rampino N, Yamamoto H, Ionov Y, Li Y, Sawai H, Reed JC, Perucho M: Frequent frameshift somatic mutations in the pro-apoptotic gene bax in colon cancer of the microsatellite mutator phenotype. Science 275:967, 1997
29. Cheng EH-Y, Levine B, Boise LH, Thompson CB, Hardwick JM: Bax-independent inhibition of apoptosis by Bcl-XL. Nature 379:554, 1996
30. Middleton G, Nunez G, Davies AM: Bax promotes neuronal survival and antagonises the survival effects of neurotrophic factors. Development 122:695, 1996
31. Minn AJ, Boise LH, Thompson CB: Bcl-XS antagonizes the protective effects of Bcl-XL. J Biol Chem 271:6306, 1996
32. Simonian PL, Grillot DAM, Merino R, Nunez G: Bax can antagonize Bcl-XL during etoposide and cisplatin-induced cell death independently of its heterodimerization with Bcl-XL. J Biol Chem 271:22764, 1996
33. Oh JH, O'Malley KL, Krajewski S, Reed JC, Oh YJ: Bax accelerates staurosporine-induced but suppresses nigericin-induced neuronal cell death. Neuro Report 8:1851, 1997
34. Muchmore SW, Sattler M, Liang H, Meadows RP, Harlan JE, Yoon HS, Nettesheim D, Changs BS. Thompson CB, Wong S, Ng S, Fesik SW: X-ray and NMR structure of human Bcl-XL, an inhibitor of programmed cell death. Nature 381:335, 1996
35. Minn AJ, Valez PR, Schendel SL, Liang H, Muchmore SW, Fesik SW, Fill M, Thompson CB: BclX forms an ion channel in synthetic lipid membranes. Nature 385:353, 1997
36. Schendel SL, Xie Z, Montal MO, Matsuyama S, Montal M, Reed JC: Channel formation by anti-apoptotic protein, Bcl-2. Proc Natl Acad Sci USA 94:5113, 1997
37. Antonsson B, Conti F, Ciavatta A, Montessuit S, Lewis S, Martinou I, Bernasconi L, Bernard A, Mermod J-J, Mazzei G, Maudrell K, Gambale F, Sadoul R, Martinou J-C: Inhibition of Bax channel-forming activity by Bcl-2. Science 277:370, 1997
38. Pietenpol JA, Papadopoulos N, Markowitz S, Willson KV, Kinzler KW, Vogelstein B: Paradoxical inhibition of solid tumor cell growth by bcl-2. Cancer Res 54:3714, 1994
39. Borner C: Diminished cell proliferation associated with the death-protective activity of Bcl-2. J Biol Chem 271:12695, 1996
40. Mazel S, Burtrum D, Petrie HT: Regulation of cell division cycle progression by bcl-2 expression: A potential mechanism for inhibition of programmed cell death. J Exp Med 183:2219, 1996
41. Linette GP, Li Y, Roth K, Korsmeyer SJ: Cross talk between cell death and cell cycle progression: BCL-2 regulates NFAT-medicated activation. Proc Natl Acad Sci USA 93:9545, 1996